^
Association details:
| Biomarker: | SETD2 mutation + RUNX1 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | ziftomenib (KO-539) (Menin-MLL inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
115 Preliminary Data on a Phase 1/2A First in Human Study of the Menin-KMT2A (MLL) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Published date:
11/04/2020
Excerpt:
A third pt (100 mg dose level) with SETD2 and RUNX1 co-mutations achieved a complete remission with confirmed negative MRD by flow cytometry after two cycles of therapy and continues on treatment....KO-539 in relapsed AML is encouraging, and its unique PK characteristics may be advantageous for clinical benefit.
Trial ID:
Source:
Title:
64 Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Published date:
11/03/2022
Excerpt:
We present here preliminary KOMET-001 (NCT04067336) data, an ongoing Phase (P) 1/2 study of ziftomenib (KO-539), an inhibitor of KMT2A-menin interaction, in adult pts with relapsed/refractory (R/R) AML….At 100 mg, 1 complete remission (CR) was observed in a pt with SETD2, RUNX1 mutations.
DOI:
https://doi.org/10.1182/blood-2022-167412
Trial ID:
